Smoothened Homolog (Protein Gx or SMO) - Drugs In Development, 2021
Summary Smoothened Homolog (Protein Gx or SMO) – Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog’s proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.
Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 4, 3, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Immunology, Infectious Disease, Respiratory and Undisclosed which include indications Medulloblastoma, Adenocarcinoma Of The Gastroesophageal Junction, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Myelomonocytic Leukemia (CMML), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bone Disorders, Coccidioidomycosis, Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrosis, Graft Versus Host Disease (GVHD), Idiopathic Pulmonary Fibrosis, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Small-Cell Lung Cancer and Unspecified.
The latest report GMDHC3047TDB – Smoothened Homolog – Drugs In Development, 2021, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO) - The report reviews Smoothened Homolog (Protein Gx or SMO)) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects - The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 22.214.171.124)Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 126.96.36.199) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The global automated liquid handling market reached a value of US$ 910.1 Million in 2021. Looking forward, the analyst expects the market to reach a value of US$ 1,501.4 Million by 2027, exhibiting a CAGR of 8.40% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well...
Osteogenesis Imperfecta Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Osteogenesis Imperfecta - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players,...
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Toll Like Receptor 8 - Drugs In Development, 2022’; Toll Like Receptor 8 (CD288 or TLR8) pipeline...
Report Scope: The scope of this report covers various types of products available in the organ-on-a-chip market and potential application sectors in various industries.The organ-on-a-chip market is broken down into various segments. Revenue forecasts from 2019 to 2026 are given for each type, application, offering...
The global CRO services market is estimated to grow at a CAGR of 11.0% during the forecast period. Growth in the CRO services market can mainly be attributed to factors such as the increasing investment in pharmaceutical R&D, rising number of clinical trials, high cost of in-house drug development (encouraging pharma-biotech companies to opt...
175 pages •
By The Business Research Company
• Mar 2022
Major players in the biosimulation market are Certara, Dassault Systèmes, Schrödinger Inc., Simulations Plus Inc., Rhenovia Pharma, Insilico Biotechnology AG, Genedata AG, Entelos Inc., Physiomics plc, Rosa & Co. LLC., In silico biosciences Inc., INOSIM Software, LeadInvent Technologies, Nuventra Pharma and Archimedes. The global biosimulation...
Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides...
120 pages •
By Infiniti Research Limited
• Mar 2022
Global Glycobiology Market 2022-2026 The analyst has been monitoring the glycobiology market and it is poised to grow by $ 1.13 bn during 2022-2026, progressing at a CAGR of 14.84% during the forecast period. Our report on the glycobiology market provides a holistic analysis, market size and forecast, trends, growth drivers,...
421 pages •
By Roots Analysis Private Ltd.
• Feb 2022
INTRODUCTION Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery...
The global IVD contract research organization market is expected to grow from US$ 4,738.79 million in 2021 to US$ 8,019.53 million by 2028; it is estimated to grow at a CAGR of 7.8% from 2021 to 2028. The rising prevalence of infectious diseases increases the demand for IVD and clinical trials along with new product launches, which...
In Vitro Diagnostics
Gross Domestic Product
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.